10MO: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial

N. Girard, Wei Li, A.I. Spira, Jerome A. Feldman, Mei Ting Mak, Maxwell Sauder, F. Bozorgmehr, P-J. Voon, Cheng‐Ta Yang, J. Cundom, Jorgé Nieva, P. Tomasini, I. Cicin, T. Romero, S. Sheng, J. Bauml, Jorge Simões, P. Mahadevia, Mark Wildgust, B.C. Cho